Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 44, Issue 3, 2003, Pages 477-481

  Savage, David G ^a   Cohen, Neil S ^b   Hesdorffer, Charles S ^a   Heitjan, Daniel ^a   Oster, Martin W ^a   Garrett, Thomas J ^a   Bar, Michael ^b   Del Prete, Salvatore ^b   March, Robert ^a   Lonberg, Mathew ^a   Talbot, Susan ^a   Mears, J Gregory ^a   Flamm, Michael ^a   Taub, Robert N ^a   Nichols, Gwen ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b STAMFORD HOSPITAL   (United States)

Author keywords

Chronic lymphocytic leukemia; Fludarabine; Lymphoma; Rituximab

Indexed keywords

ALLOPURINOL; FLUDARABINE; RITUXIMAB;

ADULT; AGED; ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD TOXICITY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER REGRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; LEUKOPENIA; LYMPHOMA; MALE; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; SEPTIC SHOCK; SKIN MANIFESTATION; SPLENECTOMY; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANAPHYLAXIS; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOMA, LOW-GRADE; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; TREATMENT OUTCOME; VIDARABINE;

EID: 0037347898     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819021000046958     Document Type: Article

References (41)

1. Hiddeman, W., Rottmann, R., Wormann, B., Thiel, A., Essink, M., Ottensmeier, C., Freund, M., Buchner, T. and van de Loo, J. (1991) "Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase II study", Ann. Hematol. 63, 1-4.
2. Redman, J.R., Cabanillas, F., Velasquez, W.S., McLaughlin, P., Hagemeister, F.B., Swan, F, Jr., Rodriguez, M.A., Plunkett, W.K. and Keating, M.J. (1991) "Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma", J. Clin. Oncol. 10, 790-794.
3. Hochster, H.S., Kim, K., Green, M.D., Mann, R.B., Neiman, R.S., Oken, M.M., Cassileth, P.A., Stott, P., Ritch, P. and O'Connell, M.J. (1992) "Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study", J. Clin. Oncol. 10, 28-32.
4. Solal-Céligny, P., Brice, P., Brousse, N., Caspard, H., Bastion, Y., Haioun, C., Bosly, A., Tilly, H., Bordessoule, D., Sebban, C., Harousseau, J.L., Morel, P., Dupas, B., Plassart, F., Vasile, N., Fort, N. and Leporrier, M. (1996) "Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte", J. Clin. Oncol. 14, 514-519.
5. Johnson, S., Smith, A.G., Osby, E., Juliusson, G., Emmerich, B., Wyld, P.J. and Hiddemann, W. (1996) "Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL", Lancet 347, 1432-1438.
6. Sorensen, J.M., Vena, D.A., Fallavollita, A., Chun, H.G. and Cheson, B.D. (1997) "Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the Group C protocol mechanism of the National Cancer Institute: five-year follow-up report", J. Clin. Oncol. 15, 458-465.
7. Leblond, V., Ben-Othman, T., Deconinck, E., Taksin, A.L., Harousseau, J.L., Delgado, M.A., Delmer, A., Maloisel, F., Mariette, X., Morel, P., Clauvel, J.P., Duboisset, P., Entezam, S., Hermine, O., Merlet, M., Yakoub-Agha, I., Guibon, O., Caspard, H., and Fort, N. (1998) "Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases", J. Clin. Oncol. 16, 2060-2064.
8. Keating, M.J., O'Brien, S., Lerner, S., Koller, C., Beran, M., Robertson, L.E., Freireich, E.J., Estey, E. and Kantarjian, H. (1998) "Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy", Blood 92, 1165-1171.
9. Foran, J.M., Rohatiner, A.Z.S., Coiffier, B., Barbui, T., Johnson, S.A., Hiddemann, W., Radford, J.A., Norton, A.J., Tollerfield, S.M., Wilson, M.P. and Lister, T.A. (1999) "Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma", J. Clin. Oncol. 17, 546-553.
10. Hagenbeek, A., Eghbali, H., Monfardini, S., Resegotti, E., Hoskin, J., de Wolf-Peeters, C., McLennan, K. and Teodorovic, I. (1998) "Fludarabine versus conventional CVP chemotherapy in newly diagnosed patients with stages III and IV low grade malignant non-Hodgkin's lymphoma. Preliminary results from a prospective, randomized phase III clinical trial in 381 patients", Blood 92, 315a (abstract 1294).
11. Klasa, R., Meyer, R., Shustik, C., Sawka, C., Smith, A., Grenier, J.F. and Bérubé, S. (1999) "Fludarabine versus CVP in previously treated patients with progressive low grade non-Hodgkin's lymphomas (Ig-NHL)", J. Clin. Oncol. 18, 9a (abstract 28).
12. Leporrier, M., Chevret, S., Cazin, B., Boudjerra, N., Feugier, P., Desablens, B., Rapp, M.J., Jaubert, J., Autrand, C., Divine, M., Dreyfus, B., Maloum, K., Travade, P., Dighiero, G., Binet, J.L. and Chastang, C. (2001) "Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. French Cooperative Group on Chronic Lymphocytic Leukemia", Blood 98, 2319-2325.
13. Rai, K.R., Peterson, B.L., Appelbaum, F.R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G.A., Larson, R.A., Cheson, B.D. and Schiffer, C.A. (2000) "Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia", N. Engl. J. Med. 343, 1750-1757.
14. Dhodapkar, M.V., Jacobson, J.L., Gertz, M.A., Rivkin, S.E., Roodman, G.D., Tuscano, J.M., Shurafa, M., Kyle, R.A., Crowley, J.J. and Barlogie, B. (2001) "Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003)", Blood 98, 41-48.
15. Maloney, D.G., Liles, T.M., Czerwinski, D.K., Waldichuk, C., Rosenberg, J., Grillo-López, A. and Levy, R. (1994) "Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma", Blood 84, 2457-2466.
16. Maloney, D.G., Grillo-López, A.J., Bodkin, D.J., White, C.A., Liles, T.M., Royston, I., Varns, C., Rosenberg, J. and Levy, R. (1997) "IDEC-C2B8: results of a phase I multiple dose trial in patients with relapsed non-Hodgkin's lymphoma", J. Clin. Oncol. 15, 3266-3274.
17. Maloney, D.G., Grillo-López, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., Janakiraman, N., Foon, K.A., Liles, T.M., Dallaire, B.K., Wey, K., Royston, I., Davis, T. and Levy, R. (1997) "IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma", Blood 90, 2188-2195.
18. McLaughlin, P., Grillo-López, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. and Dallaire, B.K. (1998) "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program", J. Clin. Oncol. 16, 2825-2833.
19. Byrd, J.C., White, C.A., Link, B., Lucas, M.S., Velasquez, W.S., Rosenberg, J. and Grillo-Lopez, A.J. (1999) "Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity", Ann. Oncol. 10, 1525-1527.
20. Davis, T.A., White, C.A., Grillo-López, A.J., Velasquez, W.S., Link, B., Maloney, D.G., Dillman, R.O., Williams, M.E., Mohrbacher, A., Weaver, R., Dowden, S. and Levy, R. (1999) "Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab", J. Clin. Oncol. 17, 1851-1857.
21. Nguyen, D.T., Amess, J.A., Doughthy, H., Hendry, L. and Diamond, L.W. (1999) "IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients", Eur. J. Haematol. 62, 76-81.
22. Davis, T.A., Grillo-López, A.J., White, C.A., McLaughlin, P., Czuczman, M.S., Link, B.K., Maloney, D.G., Weaver, R.L., Rosenberg, J. and Levy, R. (2000) "Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment", J. Clin. Oncol. 18, 3135-3143.
23. Foran, J.M., Cunningham, D., Coiffier, B., Solal-Céligny, P., Reyes, F., Ghielmini, M., Johnson, P.W., Gisselbrecht, C., Bradburn, M., Matthews, J. and Lister, T.A. (2000) "Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response", Ann. Oncol. 11(Suppl. 1), 117-121.
24. Foran, J.M., Gupta, R.K., Cunningham, D., Popescu, R.A., Goldstone, A.H., Sweetenham, J.W., Pettengell, R., Johnson, P.W., Bessell, E., Hancock, B., Summers, K., Hughes, J., Rohatiner, A.Z. and Lister, T.A. (2000) "A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response", Br. J. Haematol. 109, 81-88.
25. Hainsworth, J.D., Burris, III, H.A., Morrissey, L.H., Litchy, S., Scullin, D.C., Jr., Bearden, J.D, 3rd., Richards, P. and Greco, F.A. (2000) "Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma", Blood 95, 3052-3056.
26. Byrd, J.C., Murphy, T., Howard, R.S., Lucas, M.S., Goodrich, A., Park, K., Pearson, M., Waselenko, J.K., Ling, G., Grever, M.R., Grillo-López, A.J., Rosenberg, J., Kunkel, L. and Flinn, I.W. (2001) "Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates significant clinical activity and acceptable toxicity", J. Clin. Oncol. 19, 2153-2164.
27. Colombat, P., Salles, G., Brousse, N., Eftekhari, P., Soubeyran, P., Delwail, V., Deconinck, E., Haioun, C., Foussard, C., Sebban, C., Stamatoullas, A., Milpied, N., Bone, F., Taillan, B., Lederlin, P., Najman, A., Thieblemont, C., Montestruc, F., Mathieu-Bone, A., Benzohra, A. and Solal-Céligny, P. (2001) "Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation", Blood 97, 101-106.
28. O'Brien, S., Freireich, E., Andreeff, M., Lerner, S. and Keating, M. (1998) "Phase I/II study of Rituxan in chronic lymphocytic leukemia (CLL)", Blood 92, 105a (abstract).
29. Huhn, D., von Schilling, C., Wilhelm, M., Ho, A.D., Hallek, M., Kuse, R., Knauf, W., Riedel, U., Hinke, A., Srock, S., Serke, S., Peschel, C. and Emmerich, B. (2001) "Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. German Chronic Lymphocytic Leukemia Study Group", Blood 98, 1326-1331.
30. Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N. and Bonavida, B. (1997) "Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs", Cancer Biother. Radiophar. 12, 177-186.
31. Alas, S., Bonavida, B. and Emmanouilides, C. (2000) "Potentiation of fludarabine cytotoxicity on non-Hodgkin lymphoma by pentoxifylline and rituximab", Anticancer Res. 5A, 2961-2966.
32. Di Gaetano, N., Yiao, Y., Erba, E., Bassan, R., Rambaldi, A., Golay, J. and Introna, M. (2001) "Synergism between fludarbine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone", Br. J. Haematol. 114, 800-809.
33. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-López, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. and Canellos, G.P. (1999) "Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas", J. Clin. Oncol. 17, 1244-1250.
34. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. and Rai, K.R. (1996) "National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment", Blood 87, 4990-4999.
35. Byrd, J.C., Waselenko, J.K., Maneatis, T.J., Murphy, T., Ward, F.T., Monahan, B.P., Sipe, M.A., Donegan, S. and White, C.A. (1999) "Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance", J. Clin. Oncol. 17, 791-795.
36. Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V. and Engert, A. (1999) "Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)", Blood 94, 2217-2224.
37. Kunzmann, V., Ruediger, T., Hallek, M., Mueller-Hermelink, H.-K. and Wilhelm, M. (2001) "Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment", Blood 98, 1991-1992.
38. Czuczman, M.S., Fallon, A., Scarpace, A., Stewart, C., Bernstein, Z.P., McCarthy, P., Skipper, M., Brown, K., Miller, K., Wending, D., Rock, M.K., Benyunes, M., Grillo-López, A. and Bernstein, S.H. (2000) "Phase II study of rituximab in combination with fludarabine in patients with low-grade or follicular B-cell lymphoma", Blood 96, 729a, (abstract 3154).
39. Byrd, J.C., Peterson, B., Park, K., Morrison, V., Vardiman, J.W., Jacobson, R.J., Rai, K. and Larson, R.A. (2001) "Rituximab added to fludarabine improves response in previously untreated chronic lymphocytic leukemia: preliminary results from CALGB 9712", J. Clin. Oncol. 20, 280a, (abstract 1116).
40. Garica Manero, G., O'Brien, S., Cortes, J., Faderl, S., Giles, F., Albitar, M., Lerner, S., Kantarjian, H. and Keating, M. (2001) "Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL)", Blood 98, 633a (abstract 2650).
41. Cabanillas, F., McLaughlin, P., Hagemeister, F., Rodriguez, M.A., Romaguera, J.E., Younes, A., Sarris, A.H., Pro, B., Dang, N., Samaniego, F. and Lee, M.S. (2000) "Molecular responses with FND + Rituxan chemoimmunotherapy for stage IV indolent follicular non-Hodgkin's lymphoma", Blood 96, 331a (abstract 1429).